BACKGROUND: There is some evidence that systemic inflammation may be associated with survival in patients with prostate cancer; however, it is unclear whether this is independent of grade. We therefore investigated the role of inflammation-based prognostic scores, the modified Glasgow Prognostic Score (mGPS) and neutrophil lymphocyte ratio (NLR), and their associations with Gleason grade in patients with prostate cancer. METHODS: Patients from a cohort, the Glasgow Inflammation Outcome Study, who had diagnosis of prostate cancer, were included in this study. The mGPS was constructed by combining C-reactive protein and albumin whereas NLR by calculating the ratio of neutrophils to lymphocytes. We estimated 5-year relative survival and relative excess risk (RER) of death by mGPS and NLR categories after adjusting for age, socioeconomic circumstances and Gleason grade. RESULTS: In all, 897 prostate cancer patients were identified; of those 422 (47%) died during a maximum follow-up of 6.2 years. Systemic inflammation appeared to have significant prognostic value. The mGPS predicted poorer 5-year overall and relative survival independent of age, socioeconomic circumstances, disease grade and NLR. Raised mGPS also had a significant association with excess risk of death (mGPS 2: RER =2.41, 95% confidence interval 1.37-4.23) among aggressive, clinically significant prostate cancer (Gleason grades 8-10). CONCLUSIONS: The mGPS is a strong measure of systemic inflammation, when compared with NLR. Prostate cancer patients with a raised mGPS had significantly higher risk of death for overall as well high-grade disease. Inflammation-based prognostic scores predict outcome in patients with prostate cancer and should be added to their routine clinical assessment.
BACKGROUND: There is some evidence that systemic inflammation may be associated with survival in patients with prostate cancer; however, it is unclear whether this is independent of grade. We therefore investigated the role of inflammation-based prognostic scores, the modified Glasgow Prognostic Score (mGPS) and neutrophil lymphocyte ratio (NLR), and their associations with Gleason grade in patients with prostate cancer. METHODS:Patients from a cohort, the Glasgow Inflammation Outcome Study, who had diagnosis of prostate cancer, were included in this study. The mGPS was constructed by combining C-reactive protein and albumin whereas NLR by calculating the ratio of neutrophils to lymphocytes. We estimated 5-year relative survival and relative excess risk (RER) of death by mGPS and NLR categories after adjusting for age, socioeconomic circumstances and Gleason grade. RESULTS: In all, 897 prostate cancerpatients were identified; of those 422 (47%) died during a maximum follow-up of 6.2 years. Systemic inflammation appeared to have significant prognostic value. The mGPS predicted poorer 5-year overall and relative survival independent of age, socioeconomic circumstances, disease grade and NLR. Raised mGPS also had a significant association with excess risk of death (mGPS 2: RER =2.41, 95% confidence interval 1.37-4.23) among aggressive, clinically significant prostate cancer (Gleason grades 8-10). CONCLUSIONS: The mGPS is a strong measure of systemic inflammation, when compared with NLR. Prostate cancerpatients with a raised mGPS had significantly higher risk of death for overall as well high-grade disease. Inflammation-based prognostic scores predict outcome in patients with prostate cancer and should be added to their routine clinical assessment.
Authors: Antonella Zucchetto; Andrea Gini; Nitin Shivappa; James R Hébert; Carmen Stocco; Luigino Dal Maso; Silvia Birri; Diego Serraino; Jerry Polesel Journal: Int J Cancer Date: 2016-06-11 Impact factor: 7.396
Authors: Deniz Bolat; Özgü Aydoğdu; Salih Polat; Serkan Yarımoğlu; İbrahim Halil Bozkurt; Tarık Yonguç; Volkan Şen Journal: Turk J Urol Date: 2016-12-14
Authors: Michael A Hoyt; Annette L Stanton; Julienne E Bower; KaMala S Thomas; Mark S Litwin; Elizabeth C Breen; Michael R Irwin Journal: Brain Behav Immun Date: 2013-04-26 Impact factor: 7.217
Authors: Irina Lerman; Maria de la Luz Garcia-Hernandez; Javier Rangel-Moreno; Luis Chiriboga; Chunliu Pan; Kent L Nastiuk; John J Krolewski; Aritro Sen; Stephen R Hammes Journal: Mol Cancer Res Date: 2017-05-16 Impact factor: 5.852
Authors: Philipp Nuhn; Ajay M Vaghasia; Jatinder Goyal; Xian C Zhou; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis Journal: BJU Int Date: 2014-02-14 Impact factor: 5.588
Authors: W S Jang; K S Cho; K H Kim; C Y Yoon; Y J Kang; J Y Lee; W S Ham; K H Rha; S J Hong; Y D Choi Journal: Prostate Cancer Prostatic Dis Date: 2016-06-28 Impact factor: 5.554